Ignite Creation Date:
2025-12-24 @ 9:12 PM
Ignite Modification Date:
2026-02-21 @ 1:20 AM
Study NCT ID:
NCT03928704
Status:
COMPLETED
Last Update Posted:
2025-12-24
First Post:
2019-04-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Netherlands']}, 'conditionBrowseModule': {'meshes': [{'id': 'D000089183', 'term': 'Axial Spondyloarthritis'}, {'id': 'D000089202', 'term': 'Non-Radiographic Axial Spondyloarthritis'}], 'ancestors': [{'id': 'D025242', 'term': 'Spondylarthropathies'}, {'id': 'D025241', 'term': 'Spondylarthritis'}, {'id': 'D013166', 'term': 'Spondylitis'}, {'id': 'D013122', 'term': 'Spinal Diseases'}, {'id': 'D001847', 'term': 'Bone Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D000844', 'term': 'Ankylosis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D001168', 'term': 'Arthritis'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000625981', 'term': 'bimekizumab'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'UCBCares@ucb.com', 'phone': '001 844 599 2273', 'title': 'UCB', 'organization': 'Cares'}, 'certainAgreement': {'restrictionType': 'GT60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From Baseline (Day 1) until Safety Follow-Up (up to Week 68)', 'description': 'As pre-specified in SAP, Maintenance Period (MP) included AEs of SFU period for participants who did not enter OLE or discontinued early in MP. Study participants who rolled over to OLE study did not have a SFU visit. TEAEs have been reported for Safety set (SS), MS, AS0010 China Extension Participants SS and AS0010 China Extension Participants MS. Overall Period included all participants who received BKZ 160 mg Q4W during study. Overall Period arm reports repeated TEAEs from DBTP and MP.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.', 'otherNumAtRisk': 126, 'deathsNumAtRisk': 126, 'otherNumAffected': 30, 'seriousNumAtRisk': 126, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.', 'otherNumAtRisk': 128, 'deathsNumAtRisk': 128, 'otherNumAffected': 40, 'seriousNumAtRisk': 128, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)', 'description': 'At the end of the 16-week Double-Blind Treatment Period, study participants receiving placebo were re-allocated to bimekizumab treatment at Week 16. Participants from both placebo and bimekizumab arm received bimekizumab 160 mg Q4W subcutaneously from Week 16 until Week 48 during maintenance period. Participants entering the extension study received bimekizumab 160 mg Q4W subcutaneously until Week 52.', 'otherNumAtRisk': 242, 'deathsNumAtRisk': 242, 'otherNumAffected': 94, 'seriousNumAtRisk': 242, 'deathsNumAffected': 0, 'seriousNumAffected': 9}, {'id': 'EG003', 'title': 'Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population)', 'description': 'Participants who received bimekizumab 160 mg Q4W subcutaneously from Day 1 up to Week 48 and participants who switched from placebo arm at Week 16 to receive bimekizumab 160 mg Q4W subcutaneously up to Week 48 were included in this group.', 'otherNumAtRisk': 244, 'deathsNumAtRisk': 244, 'otherNumAffected': 114, 'seriousNumAtRisk': 244, 'deathsNumAffected': 0, 'seriousNumAffected': 9}, {'id': 'EG004', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.', 'otherNumAtRisk': 11, 'deathsNumAtRisk': 11, 'otherNumAffected': 8, 'seriousNumAtRisk': 11, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.', 'otherNumAtRisk': 9, 'deathsNumAtRisk': 9, 'otherNumAffected': 9, 'seriousNumAtRisk': 9, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)', 'description': 'At the end of the 16-week Double-Blind Treatment Period, study participants in China Extension Population receiving placebo were re-allocated to bimekizumab treatment at Week 16. Participants from both placebo and bimekizumab arm received bimekizumab 160 mg Q4W subcutaneously from Week 16 until Week 48 during maintenance period. Participants entering the extension study received bimekizumab 160 mg Q4W subcutaneously until Week 52.', 'otherNumAtRisk': 20, 'deathsNumAtRisk': 20, 'otherNumAffected': 13, 'seriousNumAtRisk': 20, 'deathsNumAffected': 0, 'seriousNumAffected': 3}, {'id': 'EG007', 'title': 'Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population)', 'description': 'Participants in the China Extension Population who received bimekizumab 160 mg Q4W subcutaneously from Day 1 up to Week 48 and participants who switched from placebo arm at Week 16 to receive bimekizumab 160 mg Q4W subcutaneously up to Week 48 were included in this group.', 'otherNumAtRisk': 20, 'deathsNumAtRisk': 20, 'otherNumAffected': 16, 'seriousNumAtRisk': 20, 'deathsNumAffected': 0, 'seriousNumAffected': 3}], 'otherEvents': [{'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 13, 'numAffected': 13}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 21, 'numAffected': 18}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 34, 'numAffected': 30}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 11, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 9, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 17, 'numAffected': 15}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 26, 'numAffected': 23}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Corona virus infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 17, 'numAffected': 17}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 18, 'numAffected': 17}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Oral candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 20, 'numAffected': 17}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 25, 'numAffected': 18}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 5, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 6, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 12, 'numAffected': 10}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 18, 'numAffected': 14}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Vision blurred', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 10, 'numAffected': 9}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Injection site pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 7, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 9, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Helicobacter infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Tinea pedis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Tinea versicolour', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 6, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 9, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Chillblains', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Blood cholesterol increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Low density lipoprotein increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Liver function test abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Liver function test increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Blood bilirubin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Lymphocyte count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 4, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Hyperlipidaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Intervertebral disc protrusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Musculoskeletal stiffness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Synovial cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Oligomenorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Eczema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Dermal cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 3, 'numAffected': 2}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Mouth ulceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Axial spondyloarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}], 'seriousEvents': [{'term': 'Abdominal adhesions', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Deafness unilateral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Appendicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Tonsillitis bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Erysipelas', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Clear cell renal cell carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Intentional self-injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Nasal crusting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Cervical dysplasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}, {'term': 'Abortion induced', 'stats': [{'groupId': 'EG000', 'numAtRisk': 126, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 128, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 242, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 244, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '21.4', 'groupId': 'OG000'}, {'value': '47.7', 'groupId': 'OG001'}, {'value': '27.3', 'groupId': 'OG002'}, {'value': '33.3', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.51', 'ciLowerLimit': '2.00', 'ciUpperLimit': '6.16', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': "ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity; and no worsening at all in the remaining component.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Randomized set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Subjects at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '109', 'groupId': 'OG000'}, {'value': '118', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '22.9', 'groupId': 'OG000'}, {'value': '46.6', 'groupId': 'OG001'}, {'value': '27.3', 'groupId': 'OG002'}, {'value': '37.5', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.08', 'ciLowerLimit': '1.71', 'ciUpperLimit': '5.54', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': "ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity; and no worsening at all in the remaining component.", 'unitOfMeasure': 'percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Randomized Set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment. Participants analyzed are those from the RS who are TNFα inhibitor-naïve.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.55', 'spread': '0.22', 'groupId': 'OG000'}, {'value': '-3.07', 'spread': '0.21', 'groupId': 'OG001'}, {'value': '-2.09', 'spread': '0.564', 'groupId': 'OG002'}, {'value': '-2.99', 'spread': '0.571', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean difference', 'ciPctValue': '95', 'paramValue': '-1.51', 'ciLowerLimit': '-2.04', 'ciUpperLimit': '-0.98', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.220', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.91', 'ciLowerLimit': '-2.42', 'ciUpperLimit': '0.61', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 16', 'description': 'BASDAI is a well-established patient-reported endpoint assessing severity of AS symptoms. It is made of 6 items assessing severity of fatigue, spinal pain, peripheral joint pain \\& swelling, enthesitis, \\& morning stiffness (both severity and duration). Each question is rated using a numerical rating scale ranging from 0 (none) to 10 (very severe), higher score=higher symptom severity.BASDAI score is calculated by computing mean of questions 5 and 6 \\& adding it to sum of questions 1 to 4.This score is then divided by 5.Total BASDAI score ranges from 0=no disease activity to 10=maximal disease activity, higher score indicates higher symptom severity. A negative change reflects improvement.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': "The Randomized Set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment. Here, 'Number of Participants Analyzed' signifies participants who were evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '38.1', 'groupId': 'OG000'}, {'value': '68.8', 'groupId': 'OG001'}, {'value': '54.5', 'groupId': 'OG002'}, {'value': '44.4', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.69', 'ciLowerLimit': '2.17', 'ciUpperLimit': '6.26', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': "ASAS20 response is defined as relative improvements of at least 20% and absolute improvement of at least 1 unit in at least 3 of the 4 following components:1) PGADA assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities, 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI, each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity; and no worsening at all in the remaining component.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Randomized Set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.1', 'groupId': 'OG000'}, {'value': '25.8', 'groupId': 'OG001'}, {'value': '9.1', 'groupId': 'OG002'}, {'value': '33.3', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.52', 'ciLowerLimit': '2.06', 'ciUpperLimit': '9.93', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': "The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of less than or equal to (\\<=) 2 units in each of the 4 following components:1) PGADA assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity,2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities, and 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Randomized Set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.1', 'groupId': 'OG000'}, {'value': '27.3', 'groupId': 'OG001'}, {'value': '9.1', 'groupId': 'OG002'}, {'value': '11.1', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.43', 'ciLowerLimit': '2.41', 'ciUpperLimit': '12.23', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': "ASDAS-MI is achieved when there is a reduction (improvement) greater or equal to (\\>=) 2.0 in ASDAS relative to Baseline. ASDAS is calculated by adding the 5 following components: 1) 0.121 × Neck, back or hip pain (BASDAI Q2), 2) 0.058 × Duration of morning stiffness (BASDAI Q6), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling in joints (BASDAI Q3), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) \\[mg/L\\] + 1). Q2, Q3 and Q6 from BASDAI and PGADA, are all assessed on a numerical scale from 0 \\[none / not active\\] to 10 \\[very severe / very active\\]. There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 is assumed for values of hs-CRP below the lower limit of quantification (LLOQ)), but no defined upper score. Higher ASDAS scores reflect higher disease activity and participants achieving ASDAS-MI are considered to have a major improvement in their disease.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Randomized Set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '20.6', 'groupId': 'OG000'}, {'value': '45.3', 'groupId': 'OG001'}, {'value': '18.2', 'groupId': 'OG002'}, {'value': '44.4', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.31', 'ciLowerLimit': '1.87', 'ciUpperLimit': '5.84', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': "ASAS 5/6 response is defined as achieving at least 20% improvement in 5 of the following 6 components:1) PGADA assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most intense pain\\], higher score=higher pain intensity,3) BASFI assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \\[none/ 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity;5) spinal mobility (ie, lateral spinal flexion component of Bath Ankylosing Spondylitis Disease Metrology Index) on a scale ranging from 0 \\[no limitation of movement\\] to 10 \\[very severe limitation of movement\\] and 6) high sensitivity C-reactive protein (hs-CRP).", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Randomized Set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.91', 'spread': '0.22', 'groupId': 'OG000'}, {'value': '-2.39', 'spread': '0.21', 'groupId': 'OG001'}, {'value': '-0.79', 'spread': '0.340', 'groupId': 'OG002'}, {'value': '-2.03', 'spread': '0.368', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean difference', 'ciPctValue': '95', 'paramValue': '-1.48', 'ciLowerLimit': '-1.99', 'ciUpperLimit': '-0.97', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.019', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.25', 'ciLowerLimit': '-2.26', 'ciUpperLimit': '-0.24', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 16', 'description': "The BASFI is a well-established PRO measure of physical functioning used in AxSpA trials. It assesses participants' level of ability during the past week in conducting 10 physical activities on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\]. The BASFI score is the mean of the 10 item scores and ranges from 0 to 10, with lower scores indicating better physical function. A negative change in BASFI indicates improvement. The higher the negative value the better the improvement.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': "The Randomized Set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment. Here, 'Number of Participants Analyzed' signifies participants who were evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Nocturnal Spinal Pain Score Using Numeric Rating Scale (NRS) at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.71', 'spread': '0.27', 'groupId': 'OG000'}, {'value': '-3.51', 'spread': '0.25', 'groupId': 'OG001'}, {'value': '-2.41', 'spread': '0.638', 'groupId': 'OG002'}, {'value': '-3.51', 'spread': '0.658', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean difference', 'ciPctValue': '95', 'paramValue': '-1.80', 'ciLowerLimit': '-2.42', 'ciUpperLimit': '-1.18', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.199', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.09', 'ciLowerLimit': '-2.83', 'ciUpperLimit': '0.65', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 16', 'description': 'Nocturnal spinal pain experienced by participants with axial spondyloarthritis (axSpA) was assessed on a numerical rating scale ranging from 0 (no pain) to 10 (most severe pain). A lower score indicates less pain and a negative change represents an improvement.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': "The Randomized Set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment. Here, 'Number of Participants Analyzed' signifies participants who were evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.30', 'spread': '0.43', 'groupId': 'OG000'}, {'value': '-4.94', 'spread': '0.42', 'groupId': 'OG001'}, {'value': '0.18', 'spread': '0.970', 'groupId': 'OG002'}, {'value': '-1.66', 'spread': '0.967', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean difference', 'ciPctValue': '95', 'paramValue': '-2.63', 'ciLowerLimit': '-3.66', 'ciUpperLimit': '-1.61', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.170', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.84', 'ciLowerLimit': '-4.56', 'ciUpperLimit': '0.89', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 16', 'description': 'The Ankylosing Spondylitis Quality of Life (ASQoL) is an 18-item PRO measure developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and validated in the full spectrum of axial spondyloarthritis (axSpA). Each item is given a score of 1 for positive responses indicating impaired quality of life, and a score of 0 for negative responses. All item scores are summed to generate the total score ranging from 0 to 18 with a higher score indicating worse HRQoL. A negative change represents an improvement.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': "The Randomized Set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment. Here, 'Number of Participants Analyzed' signifies participants who were evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.36', 'spread': '0.79', 'groupId': 'OG000'}, {'value': '9.32', 'spread': '0.76', 'groupId': 'OG001'}, {'value': '-3.52', 'spread': '2.462', 'groupId': 'OG002'}, {'value': '3.75', 'spread': '2.364', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.96', 'ciLowerLimit': '2.08', 'ciUpperLimit': '5.83', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.035', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.27', 'ciLowerLimit': '0.60', 'ciUpperLimit': '13.95', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 16', 'description': "SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range.", 'unitOfMeasure': 'T-score', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': "Randomized Set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment. 'Number of Participants Analyzed' signifies participants who were evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '-0.44', 'spread': '0.08', 'groupId': 'OG001'}, {'value': '0.12', 'spread': '0.211', 'groupId': 'OG002'}, {'value': '-0.38', 'spread': '0.232', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.33', 'ciLowerLimit': '-0.52', 'ciUpperLimit': '-0.14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.086', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.50', 'ciLowerLimit': '-1.07', 'ciUpperLimit': '0.07', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 16', 'description': "The BASMI characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The Randomized Set consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '92', 'groupId': 'OG000'}, {'value': '94', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.11', 'spread': '0.38', 'groupId': 'OG000'}, {'value': '-2.16', 'spread': '0.37', 'groupId': 'OG001'}, {'value': '-1.35', 'spread': '0.692', 'groupId': 'OG002'}, {'value': '-1.80', 'spread': '0.871', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '=0.013', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.06', 'ciLowerLimit': '-1.88', 'ciUpperLimit': '-0.23', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 16', 'description': 'The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Subgroup of study participants in Randomized Set with enthesitis at Baseline (MASES index score \\> 0). Subgroup of study participants in China Extension Population (randomized set) with enthesitis at Baseline (MASES index score \\> 0).'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '92', 'groupId': 'OG000'}, {'value': '94', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}], 'classes': [{'categories': [{'measurements': [{'value': '23.9', 'groupId': 'OG000'}, {'value': '51.1', 'groupId': 'OG001'}, {'value': '60.0', 'groupId': 'OG002'}, {'value': '66.7', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.49', 'ciLowerLimit': '1.84', 'ciUpperLimit': '6.62', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 16', 'description': 'The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Subgroup of study participants in Randomized Set with enthesitis at Baseline (MASES index score \\> 0). Subgroup of study participants in China Extension Population (randomized set) with enthesitis at Baseline (MASES index score \\> 0).'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '242', 'groupId': 'OG002'}, {'value': '244', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}, {'value': '9', 'groupId': 'OG005'}, {'value': '20', 'groupId': 'OG006'}, {'value': '20', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)', 'description': 'At the end of the 16-week Double-Blind Treatment Period, study participants receiving placebo were re-allocated to bimekizumab treatment at Week 16. Participants from both placebo and bimekizumab arm received bimekizumab 160 mg Q4W subcutaneously from Week 16 until Week 48 during maintenance period. Participants entering the extension study received bimekizumab 160 mg Q4W subcutaneously until Week 52.'}, {'id': 'OG003', 'title': 'Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population)', 'description': 'Participants who received bimekizumab 160 mg Q4W subcutaneously from Day 1 up to Week 48 and participants who switched from placebo arm at Week 16 to receive bimekizumab 160 mg Q4W subcutaneously up to Week 48 were included in this group.'}, {'id': 'OG004', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG005', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG006', 'title': 'BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)', 'description': 'At the end of the 16-week Double-Blind Treatment Period, study participants in China Extension Population receiving placebo were re-allocated to bimekizumab treatment at Week 16. Participants from both placebo and bimekizumab arm received bimekizumab 160 mg Q4W subcutaneously from Week 16 until Week 48 during maintenance period. Participants entering the extension study received bimekizumab 160 mg Q4W subcutaneously until Week 52.'}, {'id': 'OG007', 'title': 'Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population)', 'description': 'Participants in the China Extension Population who received bimekizumab 160 mg Q4W subcutaneously from Day 1 up to Week 48 and participants who switched from placebo arm at Week 16 to receive bimekizumab 160 mg Q4W subcutaneously up to Week 48 were included in this group.'}], 'classes': [{'categories': [{'measurements': [{'value': '56.3', 'groupId': 'OG000'}, {'value': '62.5', 'groupId': 'OG001'}, {'value': '67.8', 'groupId': 'OG002'}, {'value': '75.0', 'groupId': 'OG003'}, {'value': '72.7', 'groupId': 'OG004'}, {'value': '100', 'groupId': 'OG005'}, {'value': '80.0', 'groupId': 'OG006'}, {'value': '90.0', 'groupId': 'OG007'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Baseline (Day 1) until Safety-Follow-Up (up to Week 68) (Week 48 last IMP intake + 20 weeks SFU)', 'description': 'TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU)). TEAEs were analyzed and have been reported separately for Double-Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 160 mg Q4W during the study. The overall period arm reports repeated TEAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, Maintenance Period (MP) included AEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Set consisted of all randomized study participants who received at least 1 dose of IMP. Maintenance Set (MS) included all study participants who have received at least 1 dose of BKZ treatment in the MP. AS0010 China Extension Participants Safety Set included all randomized study participants who received at least 1 dose of IMP. AS0010 China Extension Participants Maintenance Set included all study participants who have received at least 1 dose of BKZ treatment in the MP.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '242', 'groupId': 'OG002'}, {'value': '244', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}, {'value': '9', 'groupId': 'OG005'}, {'value': '20', 'groupId': 'OG006'}, {'value': '20', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)', 'description': 'At the end of the 16-week Double-Blind Treatment Period, study participants receiving placebo were re-allocated to bimekizumab treatment at Week 16. Participants from both placebo and bimekizumab arm received bimekizumab 160 mg Q4W subcutaneously from Week 16 until Week 48 during maintenance period. Participants entering the extension study received bimekizumab 160 mg Q4W subcutaneously until Week 52.'}, {'id': 'OG003', 'title': 'Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population)', 'description': 'Participants who received bimekizumab 160 mg Q4W subcutaneously from Day 1 up to Week 48 and participants who switched from placebo arm at Week 16 to receive bimekizumab 160 mg Q4W subcutaneously up to Week 48 were included in this group.'}, {'id': 'OG004', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG005', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG006', 'title': 'BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)', 'description': 'At the end of the 16-week Double-Blind Treatment Period, study participants in China Extension Population receiving placebo were re-allocated to bimekizumab treatment at Week 16. Participants from both placebo and bimekizumab arm received bimekizumab 160 mg Q4W subcutaneously from Week 16 until Week 48 during maintenance period. Participants entering the extension study received bimekizumab 160 mg Q4W subcutaneously until Week 52.'}, {'id': 'OG007', 'title': 'Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population)', 'description': 'Participants in the China Extension Population who received bimekizumab 160 mg Q4W subcutaneously from Day 1 up to Week 48 and participants who switched from placebo arm at Week 16 to receive bimekizumab 160 mg Q4W subcutaneously up to Week 48 were included in this group.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.8', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '3.7', 'groupId': 'OG002'}, {'value': '3.7', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '15.0', 'groupId': 'OG006'}, {'value': '15.0', 'groupId': 'OG007'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Baseline (Day 1) until Safety Follow-Up (up to Week 68)', 'description': 'A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent any of the above, 6) Initial inpatient hospitalization or prolongation of hospitalization. The overall period arm reports repeated SAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included SAEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Set consisted of all randomized study participants who received at least 1 dose of IMP. Maintenance Set (MS) included all study participants who have received at least 1 dose of BKZ treatment in the MP. AS0010 China Extension Participants Safety Set included all randomized study participants who received at least 1 dose of IMP. AS0010 China Extension Participants Maintenance Set included all study participants who have received at least 1 dose of BKZ treatment in the MP.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '128', 'groupId': 'OG001'}, {'value': '242', 'groupId': 'OG002'}, {'value': '244', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}, {'value': '9', 'groupId': 'OG005'}, {'value': '20', 'groupId': 'OG006'}, {'value': '20', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)', 'description': 'At the end of the 16-week Double-Blind Treatment Period, study participants receiving placebo were re-allocated to bimekizumab treatment at Week 16. Participants from both placebo and bimekizumab arm received bimekizumab 160 mg Q4W subcutaneously from Week 16 until Week 48 during maintenance period. Participants entering the extension study received bimekizumab 160 mg Q4W subcutaneously until Week 52.'}, {'id': 'OG003', 'title': 'Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population)', 'description': 'Participants who received bimekizumab 160 mg Q4W subcutaneously from Day 1 up to Week 48 and participants who switched from placebo arm at Week 16 to receive bimekizumab 160 mg Q4W subcutaneously up to Week 48 were included in this group.'}, {'id': 'OG004', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG005', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'OG006', 'title': 'BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)', 'description': 'At the end of the 16-week Double-Blind Treatment Period, study participants in China Extension Population receiving placebo were re-allocated to bimekizumab treatment at Week 16. Participants from both placebo and bimekizumab arm received bimekizumab 160 mg Q4W subcutaneously from Week 16 until Week 48 during maintenance period. Participants entering the extension study received bimekizumab 160 mg Q4W subcutaneously until Week 52.'}, {'id': 'OG007', 'title': 'Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population)', 'description': 'Participants in the China Extension Population who received bimekizumab 160 mg Q4W subcutaneously from Day 1 up to Week 48 and participants who switched from placebo arm at Week 16 to receive bimekizumab 160 mg Q4W subcutaneously up to Week 48 were included in this group.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.0', 'groupId': 'OG000'}, {'value': '1.6', 'groupId': 'OG001'}, {'value': '2.5', 'groupId': 'OG002'}, {'value': '3.3', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)', 'description': 'TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). The overall period arm reports repeated events from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included events of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Set consisted of all randomized study participants who received at least 1 dose of IMP. Maintenance Set (MS) included all study participants who have received at least 1 dose of BKZ treatment in the MP. AS0010 China Extension Participants Safety Set included all randomized study participants who received at least 1 dose of IMP. AS0010 China Extension Participants Maintenance Set included all study participants who have received at least 1 dose of BKZ treatment in the MP.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 milligrams (mg) every 4 weeks (Q4W) subcutaneously until Week 16.'}, {'id': 'FG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'FG002', 'title': 'Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)', 'description': 'At the end of the 16-week Double-Blind Treatment Period, study participants receiving placebo were re-allocated to bimekizumab treatment at Week 16. Participants from both placebo and bimekizumab arm received bimekizumab 160 mg Q4W subcutaneously from Week 16 until Week 48 during maintenance period. Participants entering the extension study received bimekizumab 160 mg Q4W subcutaneously until Week 52.'}, {'id': 'FG003', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'FG004', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'FG005', 'title': 'BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)', 'description': 'At the end of the 16-week Double-Blind Treatment Period, study participants in China Extension Population receiving placebo were re-allocated to bimekizumab treatment at Week 16. Participants from both placebo and bimekizumab arm received bimekizumab 160 mg Q4W subcutaneously from Week 16 until Week 48 during maintenance period. Participants entering the extension study received bimekizumab 160 mg Q4W subcutaneously until Week 52.'}], 'periods': [{'title': 'Double-Blind Treatment Period:Week 1-16', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '126'}, {'groupId': 'FG001', 'numSubjects': '128'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '11'}, {'groupId': 'FG004', 'numSubjects': '9'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Started Chinese Participants', 'achievements': [{'groupId': 'FG000', 'numSubjects': '7'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '11'}, {'groupId': 'FG004', 'numSubjects': '9'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '118'}, {'groupId': 'FG001', 'numSubjects': '126'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '11'}, {'groupId': 'FG004', 'numSubjects': '9'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Patient Compliance', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Withdrawal By Study Participant', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}]}, {'title': 'Maintenance Period: Week 16-52', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'comment': 'Placebo=116+ BKZ=126 2 participants Completed the 16-Week Double-Blind Period but did not enter the Maintenance Period because of the below reason:\n\nAdverse event:', 'groupId': 'FG002', 'numSubjects': '242'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '20'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '220'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '17'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '22'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '3'}]}], 'dropWithdraws': [{'type': 'Withdrawal By Study Participant', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '12'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'COVID-19 pandemic situation & site restrictions', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '2'}]}, {'type': 'Non- Compliance', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'The study started to enroll participants in April 2019 and concluded in April 2023. Among the total of 274 participants, 254 participants were enrolled under the global study protocol by June 2021, including 16 enrolled in China. The enrolment was extended in China to achieve the target of 36 participants as agreed with the local agency and additional 20 Chinese participants were enrolled by February 2022 in the China Extension population.', 'preAssignmentDetails': 'Out of 36 Chinese participants, 16 participants were included in the analysis of global population and the results of the remaining 20 Chinese participants are reported separately as the China Extension Population. Participant Flow refers to the Randomized Set and AS0010 China Extension Participants.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'BG000'}, {'value': '128', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '274', 'groupId': 'BG004'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo (up to Week 16) (Global Population)', 'description': 'Participants received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'BG001', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)', 'description': 'Participants received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'BG002', 'title': 'Placebo (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received placebo matched to bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'BG003', 'title': 'Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)', 'description': 'Participants in the China Extension Population received bimekizumab 160 mg Q4W subcutaneously until Week 16.'}, {'id': 'BG004', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'categories': [{'title': '18 - <65', 'measurements': [{'value': '123', 'groupId': 'BG000'}, {'value': '125', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '268', 'groupId': 'BG004'}]}, {'title': '65 - <85', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}]}, {'title': '>= 85', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '61', 'groupId': 'BG000'}, {'value': '55', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '125', 'groupId': 'BG004'}]}, {'title': 'Male', 'measurements': [{'value': '65', 'groupId': 'BG000'}, {'value': '73', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '7', 'groupId': 'BG003'}, {'value': '149', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'Asian', 'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '15', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '48', 'groupId': 'BG004'}]}, {'title': 'Black', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}]}, {'title': 'White', 'measurements': [{'value': '110', 'groupId': 'BG000'}, {'value': '109', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '219', 'groupId': 'BG004'}]}, {'title': 'Other/Mixed', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}]}, {'title': 'Missing', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '122', 'groupId': 'BG000'}, {'value': '125', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '267', 'groupId': 'BG004'}]}, {'title': 'Missing', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Baseline Characteristics refer to the Randomized Set which consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-02-16', 'size': 2723844, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2024-10-18T04:47', 'hasProtocol': True}, {'date': '2021-11-12', 'size': 2765301, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2024-10-18T04:47', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 274}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-04-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'dispFirstSubmitDate': '2023-06-28', 'completionDateStruct': {'date': '2023-04-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-12-05', 'studyFirstSubmitDate': '2019-04-23', 'resultsFirstSubmitDate': '2024-10-18', 'studyFirstSubmitQcDate': '2019-04-25', 'dispFirstPostDateStruct': {'date': '2023-06-29', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2025-12-24', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-10-18', 'studyFirstPostDateStruct': {'date': '2019-04-26', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2024-11-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-06-29', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16', 'timeFrame': 'Week 16', 'description': "ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity; and no worsening at all in the remaining component."}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Subjects at Week 16', 'timeFrame': 'Week 16', 'description': "ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity; and no worsening at all in the remaining component."}, {'measure': 'Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16', 'timeFrame': 'Baseline, Week 16', 'description': 'BASDAI is a well-established patient-reported endpoint assessing severity of AS symptoms. It is made of 6 items assessing severity of fatigue, spinal pain, peripheral joint pain \\& swelling, enthesitis, \\& morning stiffness (both severity and duration). Each question is rated using a numerical rating scale ranging from 0 (none) to 10 (very severe), higher score=higher symptom severity.BASDAI score is calculated by computing mean of questions 5 and 6 \\& adding it to sum of questions 1 to 4.This score is then divided by 5.Total BASDAI score ranges from 0=no disease activity to 10=maximal disease activity, higher score indicates higher symptom severity. A negative change reflects improvement.'}, {'measure': 'Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16', 'timeFrame': 'Week 16', 'description': "ASAS20 response is defined as relative improvements of at least 20% and absolute improvement of at least 1 unit in at least 3 of the 4 following components:1) PGADA assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities, 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI, each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity; and no worsening at all in the remaining component."}, {'measure': 'Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16', 'timeFrame': 'Week 16', 'description': "The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of less than or equal to (\\<=) 2 units in each of the 4 following components:1) PGADA assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity,2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities, and 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity."}, {'measure': 'Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16', 'timeFrame': 'Week 16', 'description': "ASDAS-MI is achieved when there is a reduction (improvement) greater or equal to (\\>=) 2.0 in ASDAS relative to Baseline. ASDAS is calculated by adding the 5 following components: 1) 0.121 × Neck, back or hip pain (BASDAI Q2), 2) 0.058 × Duration of morning stiffness (BASDAI Q6), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling in joints (BASDAI Q3), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) \\[mg/L\\] + 1). Q2, Q3 and Q6 from BASDAI and PGADA, are all assessed on a numerical scale from 0 \\[none / not active\\] to 10 \\[very severe / very active\\]. There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 is assumed for values of hs-CRP below the lower limit of quantification (LLOQ)), but no defined upper score. Higher ASDAS scores reflect higher disease activity and participants achieving ASDAS-MI are considered to have a major improvement in their disease."}, {'measure': 'Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16', 'timeFrame': 'Week 16', 'description': "ASAS 5/6 response is defined as achieving at least 20% improvement in 5 of the following 6 components:1) PGADA assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most intense pain\\], higher score=higher pain intensity,3) BASFI assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \\[none/ 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity;5) spinal mobility (ie, lateral spinal flexion component of Bath Ankylosing Spondylitis Disease Metrology Index) on a scale ranging from 0 \\[no limitation of movement\\] to 10 \\[very severe limitation of movement\\] and 6) high sensitivity C-reactive protein (hs-CRP)."}, {'measure': 'Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16', 'timeFrame': 'Baseline, Week 16', 'description': "The BASFI is a well-established PRO measure of physical functioning used in AxSpA trials. It assesses participants' level of ability during the past week in conducting 10 physical activities on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\]. The BASFI score is the mean of the 10 item scores and ranges from 0 to 10, with lower scores indicating better physical function. A negative change in BASFI indicates improvement. The higher the negative value the better the improvement."}, {'measure': 'Change From Baseline in Nocturnal Spinal Pain Score Using Numeric Rating Scale (NRS) at Week 16', 'timeFrame': 'Baseline, Week 16', 'description': 'Nocturnal spinal pain experienced by participants with axial spondyloarthritis (axSpA) was assessed on a numerical rating scale ranging from 0 (no pain) to 10 (most severe pain). A lower score indicates less pain and a negative change represents an improvement.'}, {'measure': 'Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16', 'timeFrame': 'Baseline, Week 16', 'description': 'The Ankylosing Spondylitis Quality of Life (ASQoL) is an 18-item PRO measure developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and validated in the full spectrum of axial spondyloarthritis (axSpA). Each item is given a score of 1 for positive responses indicating impaired quality of life, and a score of 0 for negative responses. All item scores are summed to generate the total score ranging from 0 to 18 with a higher score indicating worse HRQoL. A negative change represents an improvement.'}, {'measure': 'Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16', 'timeFrame': 'Baseline, Week 16', 'description': "SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range."}, {'measure': 'Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16', 'timeFrame': 'Baseline, Week 16', 'description': "The BASMI characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement."}, {'measure': 'Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16', 'timeFrame': 'Baseline, Week 16', 'description': 'The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.'}, {'measure': 'Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline', 'timeFrame': 'Baseline, Week 16', 'description': 'The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.'}, {'measure': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study', 'timeFrame': 'From Baseline (Day 1) until Safety-Follow-Up (up to Week 68) (Week 48 last IMP intake + 20 weeks SFU)', 'description': 'TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU)). TEAEs were analyzed and have been reported separately for Double-Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 160 mg Q4W during the study. The overall period arm reports repeated TEAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, Maintenance Period (MP) included AEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.'}, {'measure': 'Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study', 'timeFrame': 'From Baseline (Day 1) until Safety Follow-Up (up to Week 68)', 'description': 'A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent any of the above, 6) Initial inpatient hospitalization or prolongation of hospitalization. The overall period arm reports repeated SAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included SAEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.'}, {'measure': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study', 'timeFrame': 'From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)', 'description': 'TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). The overall period arm reports repeated events from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included events of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Nonradiographic axial spondyloarthritis', 'Axial spondyloarthritis', 'Nr-axSpA', 'Bimekizumab'], 'conditions': ['Nonradiographic Axial Spondyloarthritis']}, 'referencesModule': {'references': [{'pmid': '36649967', 'type': 'RESULT', 'citation': 'van der Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, Elewaut D, Ellis AM, Fleurinck C, Gaffney K, Gensler LS, Haroon N, Magrey M, Maksymowych WP, Marten A, Massow U, Oortgiesen M, Poddubnyy D, Rudwaleit M, Shepherd-Smith J, Tomita T, Van den Bosch F, Vaux T, Xu H. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023 Apr;82(4):515-526. doi: 10.1136/ard-2022-223595. Epub 2023 Jan 17.'}, {'pmid': '38599650', 'type': 'RESULT', 'citation': 'Navarro-Compan V, Ramiro S, Deodhar A, Mease PJ, Rudwaleit M, de la Loge C, Fleurinck C, Taieb V, Morup MF, Massow U, Kay J, Magrey M. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD Open. 2024 Apr 10;10(2):e004040. doi: 10.1136/rmdopen-2023-004040.'}, {'pmid': '38834351', 'type': 'RESULT', 'citation': 'Dubreuil M, Navarro-Compan V, Boonen A, Gaffney K, Gensler LS, de la Loge C, Vaux T, Fleurinck C, Massow U, Taieb V, Morup MF, Deodhar A, Rudwaleit M. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD Open. 2024 Jun 4;10(2):e004202. doi: 10.1136/rmdopen-2024-004202.'}, {'pmid': '39133438', 'type': 'RESULT', 'citation': 'Cella D, de la Loge C, Fofana F, Guo S, Ellis A, Fleurinck C, Massow U, Dougados M, Navarro-Compan V, Walsh JA. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation. J Patient Rep Outcomes. 2024 Aug 12;8(1):92. doi: 10.1186/s41687-024-00769-x.'}, {'pmid': '41125403', 'type': 'RESULT', 'citation': 'Ramiro S, Poddubnyy D, Mease PJ, Lopez-Medina C, Kim M, Massow U, Taieb V, Kragstrup TW, McGonagle D. Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis. RMD Open. 2025 Oct 22;11(4):e005969. doi: 10.1136/rmdopen-2025-005969.'}, {'pmid': '41314667', 'type': 'DERIVED', 'citation': "Marzo-Ortega H, Navarro-Compan V, Dubreuil M, Mease PJ, Magrey M, Rudwaleit M, D'Agostino MA, Gaffney K, Kay J, de la Loge C, Massow U, Taieb V, Vaux T, Deodhar A. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. 2025 Nov 28;11(4):e006013. doi: 10.1136/rmdopen-2025-006013."}, {'pmid': '40194794', 'type': 'DERIVED', 'citation': 'Mease PJ, Gensler LS, Orbai AM, Warren RB, Bajracharya R, Ink B, Marten A, Massow U, Shende V, Manente M, Peterson L, White K, Landewe R, Poddubnyy D. Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies. RMD Open. 2025 Apr 6;11(2):e005026. doi: 10.1136/rmdopen-2024-005026.'}, {'pmid': '39406403', 'type': 'DERIVED', 'citation': 'Navarro-Compan V, Rudwaleit M, Dubreuil M, Magrey M, Marzo-Ortega H, Mease PJ, Walsh JA, Dougados M, de la Loge C, Fleurinck C, Massow U, Vaux T, Taieb V, Deodhar A. Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies. J Rheumatol. 2025 Jan 1;52(1):23-32. doi: 10.3899/jrheum.2024-0223.'}, {'pmid': '37793792', 'type': 'DERIVED', 'citation': 'Baraliakos X, Deodhar A, van der Heijde D, Magrey M, Maksymowych WP, Tomita T, Xu H, Massow U, Fleurinck C, Ellis AM, Vaux T, Shepherd-Smith J, Marten A, Gensler LS. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024 Jan 11;83(2):199-213. doi: 10.1136/ard-2023-224803.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Male or female patients at least 18 years of age\n* Patient has nonradiographic axial spondyloarthritis (nr-axSpA) with all of the following criteria:\n\n 1. Adult-onset axial spondyloarthritis meeting Assessment of SpondyloArthritis International Society (ASAS) classification criteria\n 2. Inflammatory back pain for at least 3 months\n 3. Age at symptom onset of less than 45 years\n 4. NO sacroiliitis (in Anterior-Posterior pelvis or sacroiliac x-ray)\n* Active disease defined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \\>=4 AND spinal pain \\>=4 on a 0 to 10 Numeric Rating Scale\n* Objective inflammation defined by sacroiliitis on magnetic resonance imaging and/or elevated C-reactive protein\n* Subjects had to have either failed to respond to 2 different nonsteroidal anti-inflammatory drugs (NSAIDs) given at the maximum tolerated dose for a total of 4 weeks or have a history of intolerance to or a contraindication to NSAID therapy\n* Patients who have taken a tumor necrosis factor alpha (TNFα) inhibitor must have experienced an inadequate response or intolerance to treatment given at an approved dose for at least 12 weeks\n* Patients currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics, corticosteroids, methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) AND/OR apremilast can be allowed if they fulfill specific requirements prior to study entry\n\nExclusion Criteria:\n\n* Treatment with more than 1 TNFα inhibitor and/or more than 2 additional non-TNFα biological response modifiers, or any interleukin (IL)-17 biological response modifier\n* Active infection or history of recent serious infections\n* Viral hepatitis B or C or human immunodeficiency virus (HIV) infection\n* Any live (includes attenuated) vaccination within the 8 weeks prior to entering the study or TB (Bacillus Calmette-Guerin) vaccination within 1 year prior entering the study\n* Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or current or history of nontuberculous mycobacterium (NTMB) infection\n* Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma or in situ cervical cancer\n* Diagnosis of inflammatory conditions other than axial spondyloarthritis (axSpA), including but not limited to psoriatic arthritis, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, and reactive arthritis. Patients with a diagnosis of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease when entering the study\n* Presence of active suicidal ideation, or moderately severe major depression or severe major depression\n* Female patients who are breastfeeding, pregnant, or planning to become pregnant during the study\n* Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening"}, 'identificationModule': {'nctId': 'NCT03928704', 'acronym': 'BE MOBILE 1', 'briefTitle': 'A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis', 'organization': {'class': 'INDUSTRY', 'fullName': 'UCB Pharma'}, 'officialTitle': 'A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis', 'orgStudyIdInfo': {'id': 'AS0010'}, 'secondaryIdInfos': [{'id': '2017-003064-13', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Bimekizumab', 'description': 'Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.', 'interventionNames': ['Drug: Bimekizumab']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.', 'interventionNames': ['Drug: Bimekizumab', 'Other: Placebo']}], 'interventions': [{'name': 'Bimekizumab', 'type': 'DRUG', 'otherNames': ['BKZ', 'UCB4940'], 'description': 'Subjects will receive bimekizumab at pre-specified time-points.', 'armGroupLabels': ['Bimekizumab', 'Placebo']}, {'name': 'Placebo', 'type': 'OTHER', 'otherNames': ['PBO'], 'description': 'Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85210', 'city': 'Mesa', 'state': 'Arizona', 'country': 'United States', 'facility': 'As0010 50131', 'geoPoint': {'lat': 33.42227, 'lon': -111.82264}}, {'zip': '85032', 'city': 'Phoenix', 'state': 'Arizona', 'country': 'United States', 'facility': 'As0010 50052', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '85351', 'city': 'Sun City', 'state': 'Arizona', 'country': 'United States', 'facility': 'As0010 50062', 'geoPoint': {'lat': 33.59754, 'lon': -112.27182}}, {'zip': '91786', 'city': 'Upland', 'state': 'California', 'country': 'United States', 'facility': 'As0010 50060', 'geoPoint': {'lat': 34.09751, 'lon': -117.64839}}, {'zip': '32174', 'city': 'Ormond Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'As0010 50059', 'geoPoint': {'lat': 29.28581, 'lon': -81.05589}}, {'zip': '34239', 'city': 'Sarasota', 'state': 'Florida', 'country': 'United States', 'facility': 'As0010 50056', 'geoPoint': {'lat': 27.33643, 'lon': -82.53065}}, {'zip': '21740', 'city': 'Hagerstown', 'state': 'Maryland', 'country': 'United States', 'facility': 'As0010 50015', 'geoPoint': {'lat': 39.64176, 'lon': -77.71999}}, {'zip': '63141', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'As0010 50016', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '97239-3011', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'As0010 50055', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '16635', 'city': 'Duncansville', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'As0010 50020', 'geoPoint': {'lat': 40.42341, 'lon': -78.4339}}, {'zip': '38119-5214', 'city': 'Memphis', 'state': 'Tennessee', 'country': 'United States', 'facility': 'As0010 50012', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}}, {'zip': '75231', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'As0010 50057', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75150', 'city': 'Mesquite', 'state': 'Texas', 'country': 'United States', 'facility': 'As0010 50036', 'geoPoint': {'lat': 32.7668, 'lon': -96.59916}}, {'zip': '99204', 'city': 'Spokane', 'state': 'Washington', 'country': 'United States', 'facility': 'As0010 50061', 'geoPoint': {'lat': 47.65966, 'lon': -117.42908}}, {'city': 'Brussels', 'country': 'Belgium', 'facility': 'As0010 40004', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Genk', 'country': 'Belgium', 'facility': 'As0010 40003', 'geoPoint': {'lat': 50.965, 'lon': 5.50082}}, {'city': 'Ghent', 'country': 'Belgium', 'facility': 'As0010 40001', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'city': 'Merksem', 'country': 'Belgium', 'facility': 'As0010 40002', 'geoPoint': {'lat': 51.24623, 'lon': 4.44903}}, {'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'As0010 40006', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'As0010 40007', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'As0010 40005', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'As0010 40008', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Beijing', 'country': 'China', 'facility': 'As0010 20040', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'city': 'Chengdu', 'country': 'China', 'facility': 'As0010 20021', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'city': 'Guangzhou', 'country': 'China', 'facility': 'As0010 20019', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'city': 'Hefei', 'country': 'China', 'facility': 'As0010 20034', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'city': 'Nanjing', 'country': 'China', 'facility': 'As0010 20024', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'city': 'Shanghai', 'country': 'China', 'facility': 'As0010 20018', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'city': 'Shanghai', 'country': 'China', 'facility': 'As0010 20020', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'city': 'Shanghai', 'country': 'China', 'facility': 'As0010 20026', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'city': 'Wenzhou', 'country': 'China', 'facility': 'As0010 20025', 'geoPoint': {'lat': 27.99942, 'lon': 120.66682}}, {'city': 'Brno', 'country': 'Czechia', 'facility': 'As0010 40011', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'city': 'Pardubice', 'country': 'Czechia', 'facility': 'As0010 40009', 'geoPoint': {'lat': 50.04075, 'lon': 15.77659}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'As0010 40013', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'As0010 40014', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'As0010 40015', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'As0010 40016', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Uherské Hradiště', 'country': 'Czechia', 'facility': 'As0010 40010', 'geoPoint': {'lat': 49.06975, 'lon': 17.45969}}, {'city': 'Zlín', 'country': 'Czechia', 'facility': 'As0010 40012', 'geoPoint': {'lat': 49.22645, 'lon': 17.67065}}, {'city': 'Boulogne-Billancourt', 'country': 'France', 'facility': 'As0010 40018', 'geoPoint': {'lat': 48.83545, 'lon': 2.24128}}, {'city': 'Limoges', 'country': 'France', 'facility': 'As0010 40022', 'geoPoint': {'lat': 45.83362, 'lon': 1.24759}}, {'city': 'Berlin', 'country': 'Germany', 'facility': 'As0010 40025', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': 'Hamburg', 'country': 'Germany', 'facility': 'As0010 40029', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'city': 'Hanover', 'country': 'Germany', 'facility': 'As0010 40024', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'city': 'Herne', 'country': 'Germany', 'facility': 'As0010 40027', 'geoPoint': {'lat': 51.5388, 'lon': 7.22572}}, {'city': 'Leipzig', 'country': 'Germany', 'facility': 'As0010 40078', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'city': 'Ratingen', 'country': 'Germany', 'facility': 'As0010 40026', 'geoPoint': {'lat': 51.29724, 'lon': 6.84929}}, {'city': 'Debrecen', 'country': 'Hungary', 'facility': 'As0010 40032', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'city': 'Szeged', 'country': 'Hungary', 'facility': 'As0010 40031', 'geoPoint': {'lat': 46.253, 'lon': 20.14824}}, {'city': 'Székesfehérvár', 'country': 'Hungary', 'facility': 'As0010 40033', 'geoPoint': {'lat': 47.18995, 'lon': 18.41034}}, {'city': 'Szombathely', 'country': 'Hungary', 'facility': 'As0010 40080', 'geoPoint': {'lat': 47.23088, 'lon': 16.62155}}, {'city': 'Chūōku', 'country': 'Japan', 'facility': 'As0010 20030', 'geoPoint': {'lat': 33.63867, 'lon': 130.67068}}, {'city': 'Iruma-gun', 'country': 'Japan', 'facility': 'As0010 20039'}, {'city': 'Kawachi-Nagano', 'country': 'Japan', 'facility': 'As0010 20036', 'geoPoint': {'lat': 34.44108, 'lon': 135.58283}}, {'city': 'Kita-gun', 'country': 'Japan', 'facility': 'As0010 20045'}, {'city': 'Kitakyushu', 'country': 'Japan', 'facility': 'As0010 20065', 'geoPoint': {'lat': 33.85181, 'lon': 130.85034}}, {'city': 'Nankoku-shi', 'country': 'Japan', 'facility': 'As0010 20038'}, {'city': 'Osaka', 'country': 'Japan', 'facility': 'As0010 20037', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'city': 'Saga', 'country': 'Japan', 'facility': 'As0010 20084', 'geoPoint': {'lat': 33.23333, 'lon': 130.3}}, {'city': 'Saitama', 'country': 'Japan', 'facility': 'As0010 20048', 'geoPoint': {'lat': 35.90807, 'lon': 139.65657}}, {'city': 'Sapporo', 'country': 'Japan', 'facility': 'As0010 20031', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'city': 'Tokyo', 'country': 'Japan', 'facility': 'As0010 20035', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Elblag', 'country': 'Poland', 'facility': 'As0010 40038', 'geoPoint': {'lat': 54.1522, 'lon': 19.40884}}, {'city': 'Krakow', 'country': 'Poland', 'facility': 'As0010 40042', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'city': 'Lublin', 'country': 'Poland', 'facility': 'As0010 40037', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'city': 'Poznan', 'country': 'Poland', 'facility': 'As0010 40044', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'city': 'Torun', 'country': 'Poland', 'facility': 'As0010 40040', 'geoPoint': {'lat': 53.01375, 'lon': 18.59814}}, {'city': 'Warsaw', 'country': 'Poland', 'facility': 'As0010 40041', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'city': 'Wroclaw', 'country': 'Poland', 'facility': 'As0010 40039', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'city': 'Wroclaw', 'country': 'Poland', 'facility': 'As0010 40043', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'city': 'A Coruña', 'country': 'Spain', 'facility': 'As0010 40045', 'geoPoint': {'lat': 43.37135, 'lon': -8.396}}, {'city': 'Córdoba', 'country': 'Spain', 'facility': 'As0010 40046', 'geoPoint': {'lat': 37.89155, 'lon': -4.77275}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'As0010 40047', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Santiago de Compostela', 'country': 'Spain', 'facility': 'As0010 40048', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'city': 'Seville', 'country': 'Spain', 'facility': 'As0010 40049', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'As0010 40052', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'As0010 40053', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'As0010 40050', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'city': 'Izmir', 'country': 'Turkey (Türkiye)', 'facility': 'As0010 40051', 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}, {'city': 'Edinburgh', 'country': 'United Kingdom', 'facility': 'As0010 40057', 'geoPoint': {'lat': 55.95206, 'lon': -3.19648}}, {'city': 'Leeds', 'country': 'United Kingdom', 'facility': 'As0010 40056', 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'city': 'London', 'country': 'United Kingdom', 'facility': 'As0010 40054', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'Norwich', 'country': 'United Kingdom', 'facility': 'As0010 40055', 'geoPoint': {'lat': 52.62783, 'lon': 1.29834}}], 'overallOfficials': [{'name': 'UCB Cares', 'role': 'STUDY_DIRECTOR', 'affiliation': '001 844 599 2273'}]}, 'ipdSharingStatementModule': {'url': 'http://www.Vivli.org', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'CSR'], 'timeFrame': 'Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.', 'ipdSharing': 'YES', 'description': 'Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.', 'accessCriteria': 'Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'UCB Biopharma SRL', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}